

**AMENDMENTS TO THE CLAIMS**

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims**

Claims 1-13 (Canceled)

Claim 14 (Currently Amended): An isolated apo-B100 protein comprising a proteoglycan receptor<sup>+</sup> mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid substitution or deletion of at least one of Lys<sub>3363</sub>, Arg<sub>3362</sub>, or Arg<sub>3364</sub>.

Claims 15-17 (Canceled)

Claim 18 (Previously presented): The apo-B100 protein according to claim 14, wherein said mutation in Site B is at position 3363 and the lysine residue is replaced with a glutamic acid residue, and the amino acid sequence from position 3358 to 3367 is:

Thr<sub>3358</sub>-Arg<sub>3359</sub>-Leu<sub>3360</sub>-Thr<sub>3361</sub>-Arg<sub>3362</sub>-**Glu<sub>3363</sub>**-Arg<sub>3364</sub>-Gly<sub>3365</sub>-Leu<sub>3366</sub>-Lys<sub>3367</sub> (SEQ ID NO:1).

Claim 19 (Previously presented): A polypeptide comprising the amino acid sequence of Site B in the apo-B100 protein according to claim 14, wherein said Site B is flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence.

Claim 20 (Previously presented): An LDL particle comprising an apo-B100 protein according to claim 14.

Claims 21-28 (Canceled)